CLX (The Clorox Company, NYSE: CLX) — Analysis Report

Report date: 2026-09-18 · Analyst: Trading assistant (indicator-selection + evidence-based synthesis)

0. Tool & Data Status — read first

All three external market-data tools (get_stock_data, get_indicators, get_verified_market_snapshot) were called and returned NO_DATA_AVAILABLE — external data is disabled in this deployment. This means:

• No current price, OHLCV, or verified snapshot is available. The instruction that the verified snapshot be the source of truth for price/indicator claims cannot be executed; therefore no price-level, support/resistance, or historical-validation claims are made anywhere in this report — current market prices for CLX are not available in provided documents.
• No technical indicator values (SMA/EMA, MACD, RSI, Bollinger, ATR, VWMA) could be computed — indicator readings are not available in provided documents.
• The report below is built exclusively from the four permitted source documents: the QuantOrb money-flow snapshot (2026-09-17), the FY26 10-K (filed 2026-08-07), the Q4/FY26 8-K press release (2026-08-03), and the 13F-HR snapshot (2026-03-31). Any figure not in those documents is explicitly flagged.

1. Instrument & Business Profile (10-K, filed 2026-08-07)

CLX is a multinational consumer- and professional-products manufacturer, Consumer Staples / Household Products, with FY2026 net sales of $6.7 billion (FY ended June 30, 2026), ~9,200 employees, operations in ~25 countries/territories, selling in ~95 markets primarily through mass retailers, grocery, warehouse clubs, dollar stores, hardware, drug/pet/military stores, e-commerce and distributors. More than 80% of sales come from brands holding leading (#1/#2 per the excerpt, text truncated) market-share positions: Clorox, Pine-Sol, Liquid-Plumr, Poett, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, Burt's Bees, plus professional brands Purell, CloroxPro, Clorox Healthcare.

Why this matters for the setup: this is a low-beta, defensively-oriented staple — exactly the profile where an extreme oversold quantitative reading (Section 2) is most plausibly a mean-reversion candidate rather than a distress signal, provided the fundamental driver of the weakness is transitory (Section 3 argues much of it is).

2. Quantitative Signal (QuantOrb money-flow engine, 2026-09-17 US session)

• MFI reading: 4.18 — an extremely low money-flow reading, consistent with capitulation-style selling pressure by that engine's methodology.
• Signal: BUY, signal strength 0.7904 (high conviction score on the engine's own scale).
• Snapshot covers the 2026-09-17 US session (site bake of the 05:30 HKT orb run).

Critical framing: the document itself states this is a quantitative screen output, not a recommendation. MFI at ~4 is a condition, not a trigger. The correct professional treatment is: the screen generates the hypothesis; price/indicator confirmation must supply the trigger. That confirmation layer (RSI, Bollinger lower band, MACD cross, moving-average reclaim) is precisely what the disabled tools would have provided — so the trade remains unconfirmed in this report.

3. Fundamentals — Q4 FY26 print (8-K Item 2.02, 2026-08-03; NOT an earnings-call transcript)

This is the heart of the analysis, and the nuance is that the headline numbers look far worse than the underlying run-rate because of two discrete, disclosed distortions:

(a) Revenue. Q4 net sales -2% to $1.95B. The GOJO acquisition (closed April 2026; now "Clorox Purell") added ~10 points — meaning the legacy business shrank meaningfully in reported terms — but organic sales -13% were driven primarily by lapping the ERP-transition incremental shipments, worth ~13.5 points. Read carefully: on this disclosure, essentially the entire organic decline is a comp artifact from prior-year shipments pulled forward into Q4 FY25 during the ERP cutover. This excerpt does not disclose a "clean" underlying organic growth rate — that derivation is not available in provided documents — but the disclosed decomposition implies the headline -13% materially overstates demand deterioration.

(b) Gross margin. -520 bps to 41.3% (from 46.5%). Decomposition per the 8-K: ERP shipment comparison ≈ -150 bps, GOJO inventory step-up ≈ -150 bps, with the residual ~-220 bps from lower volume, higher commodity costs, and higher manufacturing/logistics costs, partially offset by cost savings. So roughly ~300 bps of the 520 bps decline is acquisition/comp noise that should not recur once the step-up is amortized through and the ERP comp laps; the remaining ~220 bps is the genuine cost/volume pressure to watch — that portion is real and is the number that matters for FY27 margin recovery modeling.

(c) EPS. Diluted GAAP EPS -50% to $1.34 (vs $2.68), burdened by GOJO transaction-related costs (inventory step-up, integration), partially offset by lapping prior-year digital/productivity investment. Adjusted EPS -42% to $1.66 (vs $2.87), attributed to lower net sales and lower gross margin — note that "lower net sales" here includes the same ERP comp distortion embedded in (a), so the adjusted decline is itself inflated by a non-run-rate item.

(d) Strategic event. The GOJO acquisition closed April 2026 and adds the Purell brand and a health/hygiene portfolio — a scale-up of the professional/health channel that complements CloroxPro/Clorox Healthcare. The step-up and integration costs are one-time in nature; the strategic logic (category leadership in hygiene) is durable.

(e) FY27 outlook. The press-release title states the company "Provides FY27 Outlook," but the outlook figures are not available in provided documents. This is a material gap: without FY27 guidance (organic growth, margin bridge, EPS) the recovery thesis cannot be quantified from the permitted evidence. Additionally, this document is the press release only — management Q&A/commentary is not available in provided documents (it is explicitly not an earnings-call transcript).

Net fundamental read: the print is optically ugly but decomposition shows a large mechanical component (ERP comp + GOJO step-up ≈ 13.5 pts of the organic decline and ~300 bps of the margin decline). The unquantified residual risk is the ~220 bps of genuine cost inflation and volume softness. An MFI of 4.18 printed after such a print is consistent with sentiment overshooting the mechanically-degraded fundamentals — the classic conditions for an oversold bounce in a defensive name — if confirmed technically.

4. Institutional Positioning (13F-HR, positions as of 2026-03-31)

Five tracked filer rows (explicitly not an exhaustive 13F universe; total tracked ≈ 1,195,441 shares, derived by summing the five rows):

Nuances and caveats: - Timing mismatch: this snapshot is 2026-03-31 — before the April GOJO close, the August 3 earnings print, and the September oversold reading. It therefore does not reflect post-earnings institutional behavior. Q2 (June 30) 13F data, reflecting the quarter the print landed in, would be the relevant read and is not available in provided documents. - Among filers with comparable prior data (only two of five), the net disclosed change is -256,674 shares (derived: -278,644 + 21,970) — a mixed-to-negative skew with the largest holder reducing hardest and a smaller fund adding. Read it as: sentiment among tracked value-leaning holders was deteriorating into spring, which is consistent with (but does not confirm) the capitulation reading the MFI is showing now. - This is a periodic regulatory disclosure with up to 45 days of statutory lag — it is not real-time positioning and must not be treated as such.

5. Indicator Battery — selection rationale and how to deploy it when data is restored

I selected 8 complementary, non-redundant indicators and attempted to compute them; all values are not available in provided documents. The selection logic and deployment rules below are the actionable framework a trader should apply the moment data access is restored:

Deployment checklist (conditions, not a recommendation): the QuantOrb BUY (0.7904) is actionable only on confluence — (i) RSI in oversold territory or turning up from it, (ii) price tagged/at boll_lb and rejecting it, (iii) macd crossing above macds or printing positive divergence, (iv) close_10_ema reclaimed as a first trend-repair tell, then close_50_sma as the primary target/resistance, while close_200_sma defines the strategic regime. Stops and size from atr multiples. If price is below the 200 SMA with no divergence, treat the signal as unconfirmed and stand down — in strong downtrends oscillators stay pinned at extremes and MFI/RSI oversold alone is not an edge.

6. Risks & What Would Invalidate the Setup

1. The residual is real: ~220 bps of the Q4 margin decline (commodities, manufacturing/logistics, volume) is not mechanical — if that persists, the "bounce" is a dead-cat move in a de-rating staple.
2. No FY27 guidance visibility: outlook figures are not available in provided documents; without them, the recovery magnitude is unquantifiable.
3. GOJO integration drag: step-up amortization and integration costs continue past the print; further one-time charges possible (not itemized in the excerpt).
4. Institutional flow is stale and negative-leaning: the largest tracked holder cut -35.4% as of March 31; if June-30 13Fs confirm broad de-allocation, the low-MFI bounce lacks sponsorship.
5. Volume/flow cross-check impossible: VWMA was deliberately excluded because volume inputs could not be retrieved — money-flow confirmation is currently single-source (QuantOrb engine).
6. ERP distortion cuts both ways: just as FY25's pull-forward inflated the comp, any current-year ERP-related shipment timing distortion would contaminate FY27 quarterly comps.

7. Key-Points Summary Table

8. Bottom Line

The permitted evidence paints a coherent picture: a defensive, franchise-quality staple whose Q4 FY26 print was mechanically degraded by the ERP comp (~13.5 pts of organic decline) and GOJO purchase accounting (~300 bps of margin decline), with a genuine-but-unquantified residual cost problem (~220 bps) and no FY27 guidance available in the permitted documents. Against that backdrop, the QuantOrb engine's MFI 4.18 / BUY 0.7904 on 2026-09-17 reads as an oversold-reversion hypothesis consistent with sentiment overshooting mechanics. It is not an entry: with all price, snapshot, and indicator tools disabled, the technical confirmation layer is missing, and nothing in the permitted documents supports any price level, support/resistance claim, or historical move. The disciplined path: treat the screen as the candidate, require RSI/Bollinger-lower/MACD confirmation plus a 10-EMA → 50-SMA repair sequence, size off ATR, verify FY27 guidance figures and June-30 institutional flows — then act.

Overall Sentiment: Mixed (Score: 5.0/10) Confidence: Low

CLX Sentiment Report — week ending 2026-09-18

Data availability caveat (critical)

All three primary sentiment sources are unavailable in this deployment: Yahoo Finance news ("NO_DATA_AVAILABLE"), StockTwits ("<unavailable>"), and Reddit ("<unavailable>"). No social or news sentiment sample exists for the 2026-09-11 to 2026-09-18 window. This report therefore relies entirely on the auxiliary sources in the analysis context: the QuantOrb money-flow snapshot (2026-09-17 session), the CLX 10-K (filed 2026-08-07), the Q4/FY26 8-K press release (2026-08-03), and a Q1-end 13F-HR holdings snapshot (as of 2026-03-31). Because the intended sentiment sources are silent and the auxiliary data is stale (13F up to ~6 months old; filings ~6 weeks old), confidence is low.

1. Source-by-source breakdown

QuantOrb money-flow engine (2026-09-17): MFI reading of 4.18 with a BUY signal at strength 0.7904 — a relatively strong technical oversold/accumulation-type screen output for CLX (Consumer Staples / Household Products). This is a quantitative screen, not a recommendation, and it reflects only the most recent session snapshot.

SEC 8-K / Q4 FY26 results (2026-08-03): Fundamentally soft quarter. Net sales -2% to $1.95B; organic sales -13% (of which ~13.5 pts from lapping ERP-transition shipments); gross margin down 520 bps to 41.3% (ERP comp and GOJO inventory step-up each ~150 bps, plus lower volume, higher commodity/manufacturing/logistics costs); diluted EPS -50% to $1.34; adjusted EPS -42% to $1.66. Offsets: the April 2026 GOJO acquisition (Purell) added ~10 pts to net sales, and management characterized results as "in line with expectations" while advancing strategic investments and providing an FY27 outlook (details not available in provided documents).

SEC 10-K (filed 2026-08-07): FY26 net sales of $6.7B, ~9,200 employees, ~25 countries, ~95 markets; portfolio of No.1 brands across Clorox, Pine-Sol, Glad, Hidden Valley, Brita, Kingsford, Fresh Step, Burt's Bees, and professional lines (Purell, CloroxPro, Clorox Healthcare); over 80% of sales from No.1 or No.2 brands. MD&A financial detail is incorporated by reference and not included in the excerpt — not available in provided documents.

13F-HR snapshot (as of 2026-03-31): Mixed institutional positioning among 5 tracked filers. Nuance Investments cut its position sharply (-278,644 shares, -35.4% to 508,145) — a notable bearish signal from the largest tracked holder; MAC Alpha added +18.7% (to 139,770) — a small bullish counterpoint. Three filers show no prior-quarter comparison (data not available in the dataset). The snapshot is stale (up to 45-day statutory lag beyond the 2026-03-31 quarter end, i.e., ~6 months old at analysis date) and not exhaustive.

2. Cross-source divergences and alignments

• Divergence: The QuantOrb BUY signal (2026-09-17) contrasts with the weak Q4 FY26 fundamentals reported in August. This is a classic value/technical vs. fundamental tension — the money-flow screen suggests the market may have already discounted the weak print, but no news/social data exists to confirm the narrative.
• Alignment (bearish): The largest tracked institutional holder's -35.4% reduction (13F, Q1) aligns directionally with the weak Q4 fundamentals, even though the 13F predates the earnings release.
• Alignment (bullish): GOJO integration (+10 pts to sales, expansion into professional health & hygiene) and the "in line with expectations" framing suggest the weakness is largely transitory (ERP lapping, inventory step-up), consistent with a contrarian/technical bounce thesis.

3. Dominant narrative themes

1. Transitory vs. structural weakness: ERP-transition shipment lapping and GOJO purchase accounting explain much of the -13% organic decline and margin compression — but volume declines and commodity/logistics cost inflation are real pressures.
2. GOJO/Purell integration: a strategic growth lever in professional health & hygiene, but near-term a source of costs (inventory step-up, integration).
3. Institutional repositioning: at least one notable holder trimming meaningfully as of Q1 2026.

4. Catalysts and risks

• Catalysts: FY27 outlook (contents not available in provided documents); GOJO synergy realization; normalization of organic comparisons post-ERP lapping; oversold technical setup per the MFI BUY screen.
• Risks: continued volume softness; commodity and logistics cost inflation; GOJO integration execution; further institutional distribution; margin recovery unproven. No news or social data available to surface more recent catalysts — not available in provided documents.

5. Key sentiment signals table

Bottom line

With all social/news sentiment sources silent, CLX reads as Mixed / neutral (5.0) on this week's sentiment data: a strong quantitative BUY screen and a credible transitory-explanations thesis (ERP lapping, GOJO step-up) sit against genuinely weak Q4 fundamentals and at least one large holder's significant trim. Traders should treat the QuantOrb BUY as a screen output, weigh the upcoming FY27 outlook and GOJO integration execution, and note that the stale institutional and social data materially limit confidence. Past sentiment and technical screens are not predictive — this is signal to weigh alongside fundamentals and price action, not a price call.

CLX (The Clorox Company, NYSE: CLX) — Trading & Macro Analysis Report

Analysis date: 2026-09-18 | Prepared by: News Research Agent

0. Tool & Data Availability Notice (read first)

All four external data tools were invoked for this workflow (get_news, get_global_news, get_macro_indicators, get_prediction_markets, covering CLX-specific news for 2026-09-11 → 2026-09-18, global macro news, FRED indicators — CPI, core PCE, unemployment, fed funds rate, 10Y Treasury, yield curve — and prediction-market probabilities). All returned NO_DATA_AVAILABLE: external market data tools are disabled in this deployment. Per protocol, this report is built exclusively from the four permitted source documents (QuantOrb FACTS snapshot, SEC 10-K excerpt, SEC 8-K press release, SEC 13F-HR snapshot). Another agent with live data access should decide the final trade.

Where a data point is missing from the permitted set, I state exactly: "not available in provided documents."

1. CLX Company Profile (SEC 10-K, filed 2026-08-07)

• Scale: Fiscal year 2026 net sales of $6.7 billion; ~9,200 employees worldwide as of June 30, 2026; operations in ~25 countries/territories, selling in ~95 markets — a diversified, mass-channel (mass retailers, grocery, clubs, dollar stores, e-commerce) consumer staples franchise.
• Brand portfolio: Clorox®, Pine-Sol®, Liquid-Plumr®, Poett®, Glad®, Fresh Step®, Kingsford®, Hidden Valley®, Brita®, Burt's Bees®; professional lines include Purell®, CloroxPro™, Clorox Healthcare®.
• Brand moat: Per the filed excerpt, "Over 80% of the Company's sales are generated from brands that hold the No. 1 or No. …" — the excerpt is truncated mid-sentence (the trailing market-position detail is not available in provided documents), but the disclosed fact stands: >80% of sales come from leading-position brands, which typically supports pricing power.
• MD&A detail resides in Exhibit 99.1, which is incorporated by reference — the substantive MD&A content is not available in provided documents.

Trading relevance: Defensive staples profile, category-leading brands, and broad channel/geographic diversification are the structural supports; the live debate for CLX is margin trajectory and post-acquisition integration (Section 2).

2. Latest Reported Fundamentals (SEC 8-K Item 2.02 press release, 2026-08-03 — Q4 & FY26)

Strategic event: In April 2026, CLX completed the acquisition of GOJO Industries (now operating as Clorox Purell), adding the Purell® brand and a health/hygiene solutions portfolio — expanding the professional business that already includes CloroxPro and Clorox Healthcare.

Q4 FY26 headline results (vs. Q4 FY25):

Analytical decomposition (derived from disclosed figures): 1. The -13% organic decline is largely optical. The ERP-transition shipment lapping alone accounts for ~13.5 pts — essentially the entire organic decline. However, "lower volume" is separately cited as a gross-margin driver, so the print is not purely mechanical; some genuine demand softness is embedded. 2. Stripping the two flagged one-offs (ERP comparison ~150 bps + GOJO inventory step-up ~150 bps = ~300 bps of the 520 bps margin decline), roughly ~220 bps of margin compression traces to ongoing pressures: lower volume, higher commodity costs, and higher manufacturing and logistics costs — the only macro-adjacent evidence permitted in this report (company-confirmed input-cost inflation in the June-2026 quarter). The exact residual split is not available in provided documents. 3. EPS decline is heavily transaction-driven. GAAP EPS halved, and even Adjusted EPS fell 42% on the sales/margin pressure — but the step-up and integration costs are deal-related and will roll off, while integration spend continues near term. 4. FY27 Outlook: The press release title states CLX "Provides FY27 Outlook," but the outlook figures themselves are not available in provided documents (excerpt truncated). This is the single most important missing document for judging whether the ~220 bps structural margin erosion persists.

3. Quantitative Money-Flow Signal (QuantOrb FACTS, 2026-09-17 US session)

• MFI reading: 4.18 — a very low reading on the conventional 0–100 Money Flow Index scale, a region classically associated with oversold conditions.
• Signal: BUY, signal strength 0.7904 — the engine is flagging strong conviction behind the buy condition on the 2026-09-17 US session (site bake of the 05:30 HKT orb run).
• Mandatory caveat per source: "The signal is a quantitative screen output, not a recommendation."

Trading relevance: A 4.18 MFI combined with a 0.79-strength BUY flag is a contrarian/mean-reversion setup: the screen is detecting depressed money flow while its composite logic turns positive. It is most credible as a tactical entry signal when (a) the fundamental overhang is genuinely transitory — which the 8-K decomposition supports for the sales line (ERP lapping), and (b) no new fundamental negative has emerged — which cannot be verified because past-week news is not available in provided documents.

4. Institutional Positioning (SEC 13F-HR, positions as of 2026-03-31)

Interpretation & caveats: - The signal is mixed: the largest tracked holder made a substantial -35.4% reduction, while one smaller filer added +18.7%. Net directional read: low conviction. - Data is stale — positions are as of 2026-03-31, roughly 5.5 months before today (2026-09-18), and pre-date both the Q4 earnings release (2026-08-03) and the GOJO close commentary. - The dataset tracks only 5 filer rows and is explicitly not exhaustive of 13F filers. Treat as anecdotal color, not a positioning consensus.

5. Current-Week News, Macro Data & Prediction Markets — Coverage Gaps

The following inputs could not be grounded and are explicitly flagged:

• CLX-specific news for the past week (2026-09-11 → 2026-09-18): not available in provided documents. Any post-8-K catalysts (analyst actions, guidance updates, the next earnings date) are not available in provided documents.
• Global macroeconomic news: not available in provided documents.
• FRED macro indicators (CPI, core PCE, unemployment, fed funds rate, 10Y Treasury, yield curve): not available in provided documents. The only permitted inflation evidence is company-sourced: CLX's own disclosure of higher commodity costs and higher manufacturing and logistics costs in its June-2026 quarter.
• Prediction markets (Fed rate cut odds, recession-2026 odds, sector events): not available in provided documents.

6. Actionable Insights for the Deciding Agent

1. Read the headline organic decline as largely transitory. ~13.5 pts of the -13% organic sales decline is ERP-shipment lapping, per the 8-K. The durable issues are (a) volume softness and (b) ~220 bps of margin pressure from commodity and manufacturing/logistics cost inflation (derived residual).
2. The quant BUY (MFI 4.18, strength 0.7904, 2026-09-17 session) frames a mean-reversion setup, consistent with a market potentially over-penalizing a comparison-distorted quarter. It is a screen output, not a recommendation.
3. The FY27 outlook (issued 2026-08-03) is the pivotal missing document. Its guidance details are not available in provided documents; any position sized before reviewing that outlook carries information risk.
4. GOJO/Purell is the strategic swing factor: it expands professional health/hygiene exposure (synergistic with CloroxPro/Clorox Healthcare), but Q4 showed transaction-related costs are still draining GAAP EPS; integration execution is a live risk through the near term.
5. Institutional flow offers no confirmation either way (one -35.4% cut, one +18.7% add, stale as of 2026-03-31, 5-filer sample).
6. Risk register for a long: continued commodity/logistics inflation; volume weakness beyond lapping effects; GOJO integration costs; unknown FY27 guidance. Risk register for staying out: missing any recovery already priced in during the ~6 weeks since the 8-K (price action since 2026-08-03: not available in provided documents).

7. Key Points Summary Table

Bottom line: The permitted evidence paints CLX as a category-leading, defensive staples franchise whose Q4 FY26 print was distorted by the ERP-transition comparison and GOJO deal costs, with a genuine underlying cost-inflation/volume margin issue (~220 bps residual) and a strong quant BUY flag (MFI 4.18, strength 0.7904) as of the 2026-09-17 session. Directionally constructive for a mean-reversion long, conditional on the missing FY27 guidance details and post-8-K newsflow — both not available in provided documents and best supplied by an agent with live data access before a trade is sized.

All four data tools (get_fundamentals, get_balance_sheet, get_cashflow, get_income_statement) returned NO_DATA_AVAILABLE — external market data access is disabled in this deployment. Per instructions, I have reasoned exclusively from the permitted source documents. Below is the comprehensive fundamental report for CLX.

CLX (The Clorox Company, NYSE: CLX) — Fundamental Research Report

Analysis date: 2026-09-18 | Sector: Consumer Staples | Industry: Household Products

1. Data Availability Notice

The external data tools for this workflow were disabled at call time. All figures below come solely from the four permitted source documents: (1) the QuantOrb money-flow snapshot, (2) the FY2026 10-K excerpt (filed 2026-08-07), (3) the 8-K Item 2.02 press release dated 2026-08-03, and (4) the 13F-HR holdings snapshot (as of 2026-03-31). Anything beyond these is flagged as "not available in provided documents."

2. Company Profile (Source: 10-K filed 2026-08-07)

• Scale: Multinational manufacturer/marketer of consumer and professional products; FY2026 net sales of $6.7 billion; ~9,200 employees worldwide as of June 30, 2026.
• Footprint: Operations in approximately 25 countries or territories; products sold in approximately 95 markets.
• Channels: Mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug/pet/military stores, third-party and owned e-commerce, and distributors — a deliberately broad, staples-typical retail mix.
• Brand portfolio (as filed): Clorox® cleaning/disinfecting, Pine-Sol®, Liquid-Plumr®, Poett®, Glad®, Fresh Step®, Kingsford®, Hidden Valley®, Brita®, Burt's Bees®; professional lines include Purell®, CloroxPro™ and Clorox Healthcare®.
• Brand leadership: Over 80% of sales are generated from brands holding the No. 1 or No. [2] share position (excerpt truncates mid-sentence; the "over 80% from No. 1 or No. 2 brands" framing is the standard reading, with the trailing text cut off in the provided excerpt).
• Structural change in FY26: In April 2026, Clorox completed the acquisition of GOJO Industries, Inc. (now operating as Clorox Purell), adding the Purell® brand and a portfolio of health and hygiene solutions — a meaningful extension of the professional/away-from-home franchise.

Note: Item 7 MD&A is incorporated by reference via Exhibit 99.1, which is not available in provided documents — so full-year margin drivers, segment results, liquidity discussion, and cash-flow narrative from the MD&A cannot be assessed here.

3. Q4 FY2026 Results (Source: 8-K press release, 2026-08-03; comparisons vs. Q4 FY25)

Analytical read-through (derived from reported figures):

1. The top-line decline is largely optical, not demand-driven — but not entirely. Organic sales fell 13%, yet ~13.5 points are attributed to lapping the ERP-transition shipment pull-forward. Stripping that, underlying organic sales were roughly flat-to-slightly-positive. However, the press release separately cites "lower volume" as a gross margin driver, indicating some genuine volume softness beyond the ERP base effect. Magnitude of that underlying volume decline: not available in provided documents.
2. Underlying margin erosion is real, even after one-timers. Of the 520 bps gross-margin decline, ~300 bps are explicitly one-off (≈150 bps ERP comp + ≈150 bps GOJO inventory step-up). That leaves ~220 bps of underlying deterioration (41.3% + 300 bps ≈ 44.3% ex-one-timers, vs. 46.5%) from lower volume, higher commodity costs, and higher manufacturing & logistics costs, only partially offset by cost savings. Inflation in inputs/logistics is the persistent pressure point.
3. Adjusted EPS -42% is the cleaner warning signal. Adjusted EPS excludes the transaction noise yet still fell 42% on lower sales and lower gross margin — the operating decline is not purely an accounting artifact of the GOJO deal.
4. GOJO integration is the FY27 swing factor. The deal added ~10 pts to Q4 sales, but the inventory step-up and integration costs are currently dragging margins and EPS. The market's focus will be on synergy realization and the accretion path. Details of the FY27 outlook (referenced in the press release title, "Provides FY27 Outlook") are not available in provided documents — the excerpt ends before the outlook section.

4. Full-Year FY2026 Financial Statements

• Income statement (full year): Only FY26 net sales of $6.7B (10-K) are available. Full-year gross margin, operating margin, net income, and FY26 total EPS are not available in provided documents.
• Balance sheet: Cash, debt, leverage, and liquidity positions are not available in provided documents. This is a material gap given the GOJO acquisition (completed April 2026) likely altered the capital structure — acquisition financing details are not available in provided documents.
• Cash flow statement: Operating cash flow, capex, and free cash flow are not available in provided documents.
• Dividend / capital returns: Not available in provided documents.

5. Quantitative Money-Flow Signal (Source: QuantOrb snapshot, 2026-09-17 US session)

• MFI reading: 4.18 | Signal: BUY | Signal strength: 0.7904
• Snapshot covers the 2026-09-17 US session (site bake of the 05:30 HKT orb run).
• Critical framing: This is a quantitative screen output, not a recommendation. A low MFI (4.18) combined with a BUY classification is characteristic of an oversold-condition screen — i.e., the machine flag is identifying capitulation-type conditions rather than confirming fundamental strength. Traders should treat it as a timing/conditioning input, not a thesis.

Timing note for the "past week" mandate: Within the past week (Sept 11–18, 2026), the only document-dated data point is the Sept 17 QuantOrb snapshot. The 8-K (Aug 3), 10-K (Aug 7), and 13F (Mar 31) are older; no intra-week news flow beyond the money-flow print is available in provided documents.

6. Institutional Positioning (Source: 13F-HR, positions as of 2026-03-31; up to 45-day statutory lag)

Read-through: - The tracked set is divided: the largest tracked holder (Nuance) cut its position by over a third, while MAC Alpha added. Net conviction signal: mildly negative-to-neutral. - Material staleness caveat: These positions are as of 2026-03-31 — they predate the GOJO closing (April 2026), the Q4 earnings miss/decline (Aug 3), and the 10-K (Aug 7). They tell us nothing about post-earnings institutional behavior. Broader ownership, hedge-fund flows, and insider transactions are not available in provided documents.

7. Synthesis: What Traders Should Take Away

1. Bull case (documented): Category-leading brand moat (>80% of sales from No. 1/No. 2 brands); diversified 95-market footprint; GOJO/Purell adds a structural professional-growth leg with ~10 pts of Q4 sales contribution; ERP distortion is a known, finite comparison problem (~13.5 pts on Q4 organic sales) that annualizes away; cost savings programs are actively offsetting some inflation.
2. Bear case (documented): Genuine volume softness plus rising commodity and manufacturing/logistics costs produced ~220 bps of underlying gross-margin erosion in Q4 even excluding one-timers; adjusted EPS fell 42%; the largest tracked institutional holder cut 35.4% of its position pre-earnings.
3. The tension traders must resolve: The QuantOrb BUY flag (MFI 4.18, strength 0.7904) suggests stretched/oversold technical conditions as of Sept 17, while the documented fundamental picture shows a transitional company (ERP reset + GOJO integration + input-cost inflation) with depressed reported and adjusted earnings. A BUY-screen trigger against this backdrop is a mean-reversion timing setup, not confirmation of an earnings inflection — and the evidence needed to confirm an inflection (FY27 guidance detail, balance sheet, cash flow) is not available in provided documents.
4. Highest-value monitorables going forward: (a) FY27 outlook specifics from the Aug 3 release (not in excerpt); (b) GOJO integration cost run-rate and synergy realization; (c) commodity/logistics cost trajectory; (d) underlying (ex-ERP) volume trends; (e) next 13F quarter-end (June 30, 2026 positions) to see whether institutions bought or sold the August earnings print.

8. Key Points Summary Table

Bottom line: CLX enters mid-September 2026 as a fundamentally sound but operationally transitional staples name — elite brands and a newly enlarged professional portfolio (GOJO/Purell), offset by genuine underlying margin pressure and a 42% adjusted-EPS decline in Q4 FY26. The QuantOrb BUY flag (MFI 4.18, 2026-09-17) marks oversold technical conditions, but the documented evidence is insufficient to confirm a fundamental inflection; the decisive inputs — FY27 guidance, balance sheet, and cash flow — are not available in provided documents.